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syndrome due to influenza virus (ARDS-influenza). Compatible with this data, we report rapid consumption
of FXII in COVID-19, but not in ARDS-influenza, plasma. Interestingly, the lag phase in fibrin
formation, triggered by the FXII activator kaolin, was not prolonged in COVID-19 as opposed to ARDS-
influenza. Using confocal and electron microscopy, we showed that increased FXII activation rate, in
conjunction with elevated fibrinogen levels, triggers formation of fibrinolysis-resistant, compact clots
with thin fibers and small pores in COVID-19. Accordingly, clot lysis was markedly impaired in COVID-19
as opposed to ARDS-infleunza subjects. Dysregulatated fibrinolytic system, as evidenced by elevated
levels of thrombin-activatable fibrinolysis inhibitor, tissue-plasminogen activator, and plasminogen
activator inhibitor-1 in COVID-19 potentiated this effect. Analysis of lung tissue sections revealed
wide-spread extra- and intra-vascular compact fibrin deposits in COVID-19 patients. Together, compact
fibrin network structure and dysregulated fibrinolysis may collectively contribute to high incidence of
thrombotic events in COVID-19.
Conflict of interest: No COI declared
COI notes: 
Preprint server: No; 
Author contributions and disclosures: M.W. designed the study, performed experiments, analyzed data, and
wrote the manuscript; A.B., L.M., and O.P. performed experiments and analyzed data; B.S., S.D., T.W.,
J.J.S., M.C.B., S.H., F.K., L.E.S., and M. Witzenrath recruited patients, analyzed patient clinical
data, and reviewed the manuscript; A-S.S. and F.S. analyzed patient clinical data and wrote the
manuscript; M.Z. and G.G. collected autopsy tissue samples and reviewed the manuscript; N.W., R.T.S.,
G.B., L.S., and P.M. analyzed data and contributed to the writing of the manuscript; W.M.K., G.K., and
K.T.P designed the study and wrote the manuscript.
Non-author contributions and disclosures: No; 
Agreement to Share Publication-Related Data and Data Sharing Statement: Data sharing requests should be
sent to Malgorzata Wygrecka (e-mail: malgorzata.wygrecka@innere.med.uni-giessen.de)

































































































































































































































































































































































































































































































































































































































































Fibrinogen (g/L)  
J) 
Figure 2  
G) 
20 μm 
Influenza SARS-CoV2/High Fibrinogen SARS-CoV2/Low Fibrinogen 
Control Influenza SARS-CoV2 
50 μm 50 μm 50 μm 
20 μm 20 μm 



































































































































































































































2 4 7 9 
- - - - 
- - - - 
9 9 9 9 
10 20 40 - 
- - - 
9 9 
- - 













































































Batroxobin - + + + 
- - + + 




























































          0    15   30   60   




FXII  - - + + + + + + + + + + 
          0    15   30   60       60   60     min   







































          0 15 30 60          0 15 30 60     
F) 

















































































































































0 1000 2000 3000 


























































2 4 7 9 
- - - - 
- - - - 
9 9 9 9 
10 20 40 - 
- - - 
9 9 
- - 











































Fibrinogen (g/L) 9 9 9 9 
E) F) G ) 





































































































































































































































































































































































    
Altered fibrin clot structure and dysregulated fibrinolysis contribute to 
thrombosis risk in severe COVID-19  
 
Malgorzata Wygrecka1†, Anna Birnhuber2, Benjamin Seeliger3†, Laura Michalick4, Oleg Pak5, 
Astrid-Solveig Schultz1, Fabian Schramm1, Martin Zacharias6, Gregor Gorkiewicz6, Sascha 
David7, Tobias Welte3†, Julius J. Schmidt8, Norbert Weissmann5†, Ralph T. Schermuly5† 
Guillermo Barreto9, 10†, Liliana Schaefer11, Philipp Markart12†, Markus C. Brack13†, Stefan 
Hippenstiel13†, Florian Kurth13†, Leif E. Sander13†, Martin Witzenrath13†, Wolfgang M. 
Kuebler4†, Grazyna Kwapiszewska2, Klaus T. Preissner14†.   
 
1
Center for Infection and Genomics of the Lung (CIGL), Universities of Giessen and Marburg Lung 
Center, Giessen, Germany. 
2
Ludwig Boltzmann Institute for Lung Vascular Research, Medical 
University of Graz, Austria. 
3
Department of Respiratory Medicine, Hannover Medical School, 
Hannover, Germany. 
4
Institute of Physiology, Charité-Universitätsmedizin, Berlin, Germany. 
5
Excellence Cluster Cardiopulmonary Institute, Universities of Giessen and Marburg Lung Center, 
Giessen, Germany. 
6
Diagnostic and Research Institute of Pathology, Medical University Graz, Austria. 
7
Institute of Intensive Care, University Hospital Zurich, Zurich, Switzerland. 
8
Department of Nephrology 
and Hypertension, Hannover Medical School, Hannover, Germany. 
9
Paris-Est Creteil University, Gly-
CRRET, Creteil, France. 
10
Laboratoire IMoPA, UMR 7365 CNRS-Université de Lorraine, Biopôle de 
l'Université de Lorraine, Campus Biologie-Santé, Faculté de Médecine, Vandœuvre-lès-Nancy Cedex, 
France.
 11
Institute of Pharmacology and Toxicology, Goethe University, Frankfurt Am Main, Germany. 
12
Department of Pulmonary Medicine, Fulda Hospital, University Medicine Marburg, Campus Fulda, 
Fulda, Germany. 
13
Department of Infectious Diseases and Respiratory Medicine, Charité 
Universitätsmedizin Berlin, Berlin, Germany. 
14
Kerckhoff-Heart-Research-Institute, Department of 
Cardiology, Medical School, Justus-Liebig-University, Giessen, Germany. 
†
Member of the German 
Center for Lung Research.  
 
To whom correspondence should be addressed:  
Malgorzata Wygrecka, PhD 
Center for Infection and Genomics of the Lung (CIGL)   
Universities of Giessen and Marburg Lung Center 
Aulweg 132, 35392 Giessen, Germany 
Phone: +49-641-99-36460; Fax: +49-641-99-36439 
E-mail: malgorzata.wygrecka@innere.med.uni-giessen.de 
 
Short title: Fibrin clot structure in COVID-19 
Abstract word count: 193 
Manuscript word count: 3961 
Figure/table count: 5/2 



































































































































The high incidence of thrombotic events suggests a possible role of the contact 
system pathway in COVID-19 pathology. Here, we demonstrate altered levels of 
factor XII (FXII) and its activation products in critically ill COVID-19 patients in 
comparison to patients with severe acute respiratory distress syndrome due to 
influenza virus (ARDS-influenza). Compatible with this data, we report rapid 
consumption of FXII in COVID-19, but not in ARDS-influenza, plasma. Interestingly, 
the lag phase in fibrin formation, triggered by the FXII activator kaolin, was not 
prolonged in COVID-19 as opposed to ARDS-influenza. Using confocal and electron 
microscopy, we showed that increased FXII activation rate, in conjunction with 
elevated fibrinogen levels, triggers formation of fibrinolysis-resistant, compact clots 
with thin fibers and small pores in COVID-19. Accordingly, clot lysis was markedly 
impaired in COVID-19 as opposed to ARDS-infleunza subjects. Dysregulatated 
fibrinolytic system, as evidenced by elevated levels of thrombin-activatable 
fibrinolysis inhibitor, tissue-plasminogen activator, and plasminogen activator 
inhibitor-1 in COVID-19 potentiated this effect. Analysis of lung tissue sections 
revealed wide-spread extra- and intra-vascular compact fibrin deposits in COVID-19 
patients. Together, compact fibrin network structure and dysregulated fibrinolysis 
may collectively contribute to high incidence of thrombotic events in COVID-19. 
 
Key points 
• Elevated fibrinogen, in conjunction with accelerated formation of FXIIa, may promote 
compact fibrin clot architecture in COVID-19. 
•  Dense fibrin network and dysregulated fibrinolysis collectively contribute to high 



































































































































Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is a corona virus 
that causes a multisystem disease emanating from the respiratory tract designated 
as a coronavirus disease (COVID)-191–3. Rapidly accumulating data suggests that a 
major underlying molecular mechanism in COVID-19-related morbidity and mortality 
is widespread endothelial injury associated with hyperactivation of the immune 
system, consequently leading to numerous haemostasis abnormalities4-8.The clinical 
relevance of these processes is highlighted by the association between abnormal 
levels of D-dimer and the 28-day mortality in patients with COVID-199-13, and post-
mortem studies stressing the presence of micro-thrombi and capillarostasis in the 
lungs of affected subjects14,15.  
The high incidence of thrombotic events, in particular deep vein thrombosis and 
pulmonary embolism, in conjunction with mildly prolonged activated partial 
thromboplastin time (APTT)16,17, suggests a possible role of coagulation factor XII 
(FXII) in COVID-19 coagulopathy. FXII is a serine protease of the contact-phase 
system of blood coagulation which circulates in plasma as a single-chain zymogen18. 
Following contact with anionic surfaces such as kaolin, but also extracellular RNA 
(eRNA) released from damaged cells19, neutrophil extracellular traps (NETs)20, or 
polyphosphates secreted from activated platelets21, FXII undergoes autoactivation to 
αFXIIa (herein referred to as FXIIa). FXIIa cleaves plasma prekallikrein (PK) to 
kallikrein (PKa), which in turn reciprocally activates FXII and amplifies FXIIa 
generation. As a consequence, the plasma kallikrein-kinin system is activated, 
leading to the release of the vasodilatory and vascular barrier disrupting peptide 
bradykinin from high molecular weight kininogen (HK)22-25. Overall, activation of the 
contact-phase system may contribute to an increased production of thrombin and 
fibrin, although FXIIa/PKa-mediated conversion of plasminogen to plasmin may also 
affect fibrinolysis26. 
A congenital deficiency of FXII in humans does not cause any bleeding 
complications, suggesting that FXII is dispensable for physiological haemostasis and 
fibrin formation27. However, the contact phase pathway may play an important role in 
thrombosis development when contact surfaces are exposed in scenarios such as 
trauma injury or bacterial and viral infections27-29. Indeed, numerous animal studies 
have confirmed a critical function of FXII in thrombus growth and stabilization under 

































































































































FXIIa inhibitors, which ensure thrombo-protection in patients without causing a 
bleeding complications27-30. 
Given the high incidence of thromboembolic complications in severely ill COVID-19 
patients16,17, we investigated the contribution of FXII to clot formation and its 
architecture in this patient cohort in comparison to patients infected with the influenza 
virus.  
 
Materials and Methods 
 
Additional methods are provided in the supplement. 
 
Study population 
Plasma samples from COVID-19 patients were obtained from the Charité-University 
Medicine, Berlin, Germany (Berlin cohort) and from the Hannover Medical School, 
Hannover, Germany (Hanover cohort). Plasma samples from acute respiratory 
distress syndrome (ARDS) due to influenza were provided from the Hannover 
Medical School, Hannover, Germany. All samples were taken within 6 days after 
onset of ARDS. All investigations were approved by the local ethics committees 
(Hanover samples: SEPSIS/ARDS Registry 8146_BO_K_2018; Berlin samples: 
EA2/066/20) and written informed consent was obtained from all participants or their 
next-of-kin. COVID-19 patients were classified as moderate (hospitalized, no invasive 
ventilation; WHO severity score: 3-4) or severe (high flow O2 or intubated and 
mechanically ventilated; WHO severity score: 5-7) as previously described31. Donor 
(healthy subjects) samples were provided by the Charité-University Medicine, Berlin, 
Germany (EA2/075/15) and from the Justus-Liebig University, Giessen, Germany 
(05/00). Blood was collected to the sodium citrate blood specimen collection tubes 
via standard venipuncture. All blood biospecimen were processed without a 
stabilizing reagent, at room temperature, within 5h of collection, and stored at -80°C. 
All plasmas were used in analyses of circulating proteins as well as coagulation and 
fibrinolytic activity except when insufficient plasma from an individual subject was 
available. Baseline demographics and clinical characteristics of the donors and 
patients are shown in Table 1.  
Lung specimens were obtained from 10 ARDS patients (5 COVID-19, 5 influenza) 

































































































































investigations were approved by the local ethics committees (Medical Faculty of 
Justus-Liebig University: 29/01 and Medical University of Graz: 32-362ex19/20) and 
written informed consent was obtained from all participants or their next-of-kin if 
required. Baseline demographics and clinical characteristics of lung tissue donors are 
shown in Table 2. 
 
Plasma clot formation and lysis 
Twenty μL of plasma were preincubated for 10min with 20μL of 0.1M imidazole 
buffer, pH7.4, and 20μL of 0.3mg/mL kaolin in a clear, flat-bottomed 96-well plate. 
Clotting was initiated by the addition of 20μL of 20mM CaCl2 in the absence or 
presence of tissue plasminogen activator (t-PA) (25ng/mL final; Sekisui Diagnostics, 
Burlington, MA). Turbidity was monitored at 405nm (A405) every 30s for 60min at 
37°C using a SpectraMax 190 (Molecular Devices, Biberach, Germany). In some 
experiments, COVID-19 plasma was preincubated with hirudin (5IE/mL final; 
Diapharma, West Chester, OH) and the clotting was induced by batroxobin (5U/mL 
final; Enzyme Research Laboratories, South Bend, IN). 
 
Fibrin formation and lysis in a purified system  
Thrombin (5nM final, Sekisui Diagnostics) was mixed with fibrinogen (2-9g/L final, 
Thermo-Fisher Scientific, Waltham, MA), pre-incubated with either FXII or FXIIa (10-
40μg/mL final, both from Sekisui Diagnostics) in a total volume of 25μL of 0.1M 
imidazole buffer in a clear, flat-bottomed 96-well plate. Fibrin formation was initiated 
by the addition of 20μL of 20mM CaCl2. To measure fibrinolysis, t-PA (0.1µg/mL final) 
and plasminogen (20µg/mL final, Enzyme Research Laboratories) were added to the 
clotting solution. Turbidity was monitored as described above. In some experiments, 
FXIIa (40μg/mL final) was preincubated with corn trypsin inhibitor (CTI; 0.01U/mL 
final, Sekisui Diagnostics) before mixing with fibrinogen. FXII and FXIII 
contaminations were not detected in fibrinogen preparation by means of western 
blotting and ELISA.  
 
FXII decay in plasma  
Endogenous FXII was depleted from plasma using the goat anti-FXII antibody (cat. 
no.: 206-0056; Zytomed Systems) covalently attached to magnetic beads (Thermo-

































































































































exogenous FXII and the sample was incubated for 1h at 37°C. Aliquots were 
withdrawn after the indicated time points and analyzed by western blotting. In some 
experiments, plasma was preincubated with 12mg/mL CTI 30min prior to the addition 
of FXII.  
Activity assays 
The PKa-like activity assay and the activity of factor VIII (FVIII:C) were performed as 
described in 32  and 33, respectively. 
 
Statistics 
Statistical analysis was performed in R (version 4) using the ggpubr package34,35. 
Data are expressed as single data points with boxplot overlay indicating median and 
interquartile range, unless indicated otherwise. Multiple groups were compared by 
non-parametric Kruskal-Wallis test. Correlations were performed using Spearman’s 
rank correlation coefficient. 
 
Data sharing statement 
For original data, please contact malgorzata.wygrecka@innere.med.uni-giessen.de 
 
Results 
FXII is activated in severely ill COVID-19 patients 
In the Berlin cohort, the plasma levels of FXII were decreased in severe COVID-19 
patients as compared to donors (Figure 1A, B; moderate: WHO severity score 3–4; 
severe: WHO severity score 5–7). Disappearance of the FXII in plasma typically 
corresponds to its activation and conversion into the two chain FXIIa protein 
composed of the 50kDa heavy chain and 30kDa light chain. Detection of FXIIa in 
plasma is, however, hindered by its rapid inactivation and complex formation with C1 
esterase inhibitor (C1INH). Thus to better monitor the presence of FXIIa in COVID-19 
plasma, we monitored products of its activation, such as cleaved HK and PKa. As 
expected, disappearance of FXII in plasma was accompanied by HK cleavage, seen 
as diminished signal intensity of the intact HK band at 130kDa (Figure 1C, D). A 
decrease in intact HK levels was associated with the appearance of cleaved HK 
fragments: the cleaved HK light chain band migrating at 55kDa and an additional 
45kDa band representing a degradation product of the 55kDa cleaved HK light chain. 

































































































































the contact system activation, we measured the activity of plasma PKa. PKa-like 
activity was markedly elevated in severe COVID-19 patients in comparison to donors 
and patients with moderate SARS-CoV2 infection (Figure 1E). Furthermore, a strong 
negative correlation between the levels of intact HK/albumin ratio and the PKa-like 
activity in plasma of severe COVID-19 patients was observed (Figure 1F). Purified 
plasma proteins and deficient plasma samples were used to demonstrate the 
specificity of the bands shown in western blots (Figure 1A, C; right panels). 
 
Fibrinogen and FXIIa regulate fibrin network density in COVID-19 
To assess whether enhanced activation of FXII in critically ill COVID-19 patients 
represents a characteristic feature of SARS-CoV-2 infection, we analyzed plasma 
samples of patients with ARDS due to influenza virus infection. The decrease in FXII 
plasma levels in severe COVID-19 in comparison to donors was confirmed in the 
independent cohort (Hanover cohort) of the patients (Figure 2A). Furthermore, the 
levels of FXII in COVID-19 were significantly lower than those in ARDS-influenza 
(Figure 2B). Surprisingly yet, the lag phase in fibrin formation, triggered by the FXII 
activator kaolin, was shorter in plasma of COVID-19 patients as compared to patients 
with ARDS-influenza (Figure 2C).  High plasma levels of FVIII:C in COVID-19 as 
opposed to ARDS-influenza provide one possible explanation for this effect  (Figure 
2D).  Notably, both COVID-19 and ARDS-influenza patients received the same daily 
dose of unfractionated heparin, excluding iatrogenic anticoagulation as a cause of 
prolonged lag phase in fibrin formation in ARDS-influenza. In addition, we excluded 
lupus anticoagulant and the presence of anti-FXII antibodies as a cause of FXII 
deficiency in COVID-19 patients in our cohort (data not shown).  
Further analysis of kaolin-triggered plasma clotting time revealed an increase in the 
time to reach the turbidity peak in both patient groups as compared to donors, but no 
difference between ARDS-influenza and COVID-19 (Figure 2E). The density of the 
clot (indicated by the maximum turbidity measurement) was higher in both patient 
groups as opposed to donors. A direct comparison between clots of ARDS-influenza 
and COVID-19 showed significantly higher maximal turbidity values in the latter group 
(Figure 2F). Visualization of fibrin clots by laser scanning confocal microscopy and 
scanning electron microscopy revealed an increase in fibrin structure compactness 
with thinner fibers and smaller pores in clots from COVID-19 plasma, as compared to 

































































































































clots generated from plasma of COVID-19 patients demonstrated association 
between packing density of fibrin fibers and plasma fibrinogen concentration, with 
dense fibrin network in clots formed in plasma of patients exhibiting high fibrinogen 
levels (Figure 2H). A strong positive correlation between maximum turbidity values 
and fibrinogen concentration in plasma of COVID-19 patients was noted (Figure 2J).  
As the architecture of fibrin clots may be influenced not only by fibrinogen but also 
FXIIa36,37, we next analyzed the impact of these two proteins on the clot structure in a 
purified system. As depicted in figure 3A high concentrations of fibrinogen increased 
peak turbidity values and this effect was potentiated by the addition of FXIIa. 
Accordingly, corn trypsin inhibitor (CTI), the inhibitor of FXIIa, reduced maximum 
turbidity of the clots generated by mixing fibrinogen and FXIIa (Figure 3B).  
As sustained activation of FXII was described in COVID-1938, we next investigated 
the potential contribution of FXIIa to the regulation of fibrin clot structure in this 
patient group. To this end, FXII-depleted COVID-19 and ARDS-influenza plasma 
samples were recalcified in the absence or presence of exogenous FXII and the fibrin 
clots were visualized using the antibody against fibrinogen/fibrin. As depicted in figure 
3C and D, FXII increased fibrin network density but not fibrin fiber diameter in 
COVID-19 plasma. Yet, no apparent effect of FXII on the clot architecture in ARDS-
influenza was observed (Figure 3C, D). Interestingly, the most prominent effect of 
FXII on fibrin network density was observed in COVID-19 plasma samples containing 
high levels of fibrinogen (Figure 3D). Together, these results imply that COVID-19 
plasma contains FXII (auto)-activation cofactor(s) which trigger generation of FXIIa. 
FXIIa then affects the fibrin clot structure in a thrombin-dependent and/or thrombin-
independent manner. In line with this assumption, rapid decay of exogenous FXII in 
COVID-19 plasma was observed (Figure 3E, F). CTI markedly delayed 
disappearance of FXII suggesting that auto-activation of FXIIa occurs in COVID-19 
and ARDS-influenza plasma samples (Figure 3E). To demonstrate a direct, thrombin-
independent, effect of FXIIa on the fibrin clot structure, we clotted hirudin-
preincubated COVID-19 plasma with batroxobin in the presence of FXIIa and/or CTI 
and measured maximum turbidity. As shown in figure 3G, FXIIa increased maximum 
turbidity and this effect was diminished by CTI. These results are in line with the 
experiments performed in the purified system (Figure 3A, B). In sum, our results 
imply that FXIIa, in addition to its possible effect on thrombin generation, may also 



































































































































Elevated fibrin network density correlates with increased clot resistance to 
fibrinolysis 
Compact fibrin network density was previously found to impair clot fibrinolysis39. 
Accordingly, we next evaluated the lysis resistance of fibrin clots in patient plasma, 
using an in vitro turbidimetric clot-lysis assay. Here, kaolin together with t-PA were 
added to plasma to initiate the intrinsic pathway of coagulation, followed by fibrin-
dependent plasmin generation via t-PA-mediated activation of plasminogen in the 
same sample.  While in donor plasma, the characteristic bell-shaped clot-lysis curve, 
representing the complete fibrin clot dissolution, was observed, only partial clot-lysis 
was detected in ARDS-influenza samples, and clot-lysis was absent in COVID-19 
samples over the entire time period of the experiment (Figure 4A). This observation is 
supported by the highest turbidity values at 60min in COVID-19 samples (Figure 4B). 
Overall, clot lysis (as assessed by turbidity values at 60min) was observed in 84% of 
ARDS-influenza patients and only 30% of COVID-19 patients suggesting pronounced 
deregulation of the fibrinolytic system in SARS-CoV2-infected subjects in our cohort. 
As expected, increasing amounts of fibrinogen and FXIIa prolonged clot lysis time, 
with an additive effect being observed at the highest concentrations of both proteins 
(Figure 4C). The addition of CTI to the assay shortened clot lysis time (Figure 4D).  
To test whether other components of the fibrinolytic system, such as t-PA, PAI-1 and 
TAFI, may be dysregulated in critically ill COVID-19 patients, we measured their 
levels by means of ELISA. The concentration of t-PA was elevated in COVID-19 as 
compared to donors and ARDS-influenza patients (Figure 4E). An increase of PAI-1 
was also noted in plasma of ARDS-influenza and COVID-19 patients as opposed to 
donors, yet, a significant difference between both patient groups was not detected 
(Figure 4F). Interestingly, TAFI was not only markedly elevated in both patient groups 
as compared to donors, but it was also higher in patients with COVID-19 as 
compared to ARDS-influenza (Figure 4G).  
 
Dense fibrin clots are observed in the lungs of severe COVID-19 patients 
To demonstrate the in vivo relevance of our findings, we stained for fibrin the autopsy 
lung tissue sections from SARS-CoV2- and influenza-infected ARDS patients as well 

































































































































autopsy was matched for all groups examined. As demonstrated in figure 5A, intra- 
and extra-vascular fibrin aggregates were observed in both severe COVID-19 and 
ARDS-influenza patients. However, in contrast to ARDS-influenza subjects, in the 
lungs of COVID-19 patients the deposits of fibrin appeared to be more widespread 
and evenly present not only in vascular but also alveolar spaces. In ARDS-influenza 
patients, fibrin deposit were predominantly observed in alveolar spaces and present 
in selected regions of the lung (Figure 5A, C). Overall, in COVID-19 lungs fibrin clots 
were more compact and homogeneous whereas in ARDS-influenza lungs they were 
widespread and characterized by regions of high and low fibrin fiber density (Figure 
5B, D).  
 
Discussion 
Many patients with severe COVID-19 exhibit coagulation abnormalities that mimic 
other systemic coagulopathies associated with severe infections, such as 
disseminated intravascular coagulation (DIC) or thrombotic microangiopathy40. A high 
incidence of venous thromboembolism, pulmonary embolism, deep vein thrombosis, 
and multiple organ failure with a poor prognosis and outcome appears to be causally 
related to dysregulation of blood coagulation in critically ill COVID-19 patients. 
Besides an elevated inflammatory status that might induce monocyte-related 
coagulation and suppression of anticoagulant pathways, typical laboratory findings in 
COVID-19 patients are increased D-dimer levels and elevated fibrinogen 
concentrations40. Moreover, inflammation-induced endothelial cell injury in different 
vascular beds may contribute to a hypercoagulable state and the risk of 
thromboembolic complications41,42. 
In order to provide mechanistic insights into the reported hypercoagulable state of 
severe COVID-19 patients, we compared changes in the contact phase system 
activation and fibrinolysis between COVID-19 patients, individuals with ARDS-
influenza, and donors (healthy subjects). While some critical parameters such as 
fibrinogen, t-PA, and TAFI were significantly increased, FXII levels were reduced in 
severe COVID-19, and the process of fibrin formation and the resulting fibrin clot 
structure and lysis were substantially different between patient cohorts. Histological 
data provided evidence for widespread, compact fibrin deposition in the lungs of 

































































































































In particular, the levels of FXII were decreased in severe COVID-19 patients as 
compared to ARDS-influenza and donors and FXII-activation products, such as 
cleaved HK and PKa-like activity, were altered in patients with SARS-CoV2 infection. 
This scenario very likely reflects FXII consumption due to its auto-activation on 
negatively charged surfaces and its reciprocal activation by PKa. Decreased FXII 
levels in COVID-19 plasma are also in accordance with moderately elevated APTT 
values reported in other studies43,44. The exacerbated consumption of FXII in severe 
COVID-19 is further supported by our in vitro studies, in which the supplementation of 
COVID-19 plasma with exogenous FXII resulted in its rapid activation, presumably 
due to the presence of FXII auto-activation cofactors or increased PKa activity. 
Indeed, common pathological events observed in COVID-19 such as increased 
tissue cell stress together with virus-mediated necrosis, endothelial dysfunction, and 
excessive neutrophil activation, lead to the release/exposure of large amounts of 
negatively charged molecules including NETs. NETs not only bind FXII but also serve 
as a potent endogenous inflammation-dependent inducer of FXII auto-activation, 
eventually propagating thrombosis45. Enhanced vascular NETosis along with 
impaired NET clearance were described in COVID-19 patients38,46.  In line with these 
findings, several studies found an increase in NET components in COVID-19 plasma 
including cell-free DNA, myeloperoxidase-DNA complexes, neutrophil elastase-DNA 
complexes, and citrullinated histone H347,48. In addition, active FXII was described to 
colocalized with NETs in the lungs of COVID-19 patients and NET positive pulmonary 
vessels were reported to be frequently clogged38,49. Together with these findings, our 
results speak for NET-induced, accelerated, and constant activation of FXII in 
COVID-19 and thus for its role in immunothrombothic processes in this pathological 
condition. In fact, FXII auto-activation cofactors were found to be relevant for the 
initiation and progression of sepsis and DIC50, 51.  
Interestingly enough, low plasma levels of FXII in severe COVID-19 patients did not 
result in the prolonged lag phase in fibrin formation, triggered by kaolin, in COVID-19 
as opposed to ARDS-influenza. High levels of FVIII:C in the former group of the 
patients may provide one possible explanation for this effect. However, further 
studies assessing the levels of other coagulation factors such as factor IX and XI and 
their inhibitors as well as thrombin-antithrombin complexes are needed to thoroughly 
characterize high procoagulant activity of COVID-19 plasma. In particular, that Bouck 

































































































































to sepsis plasma52. These results, together with previously described high levels of 
fibrinogen, mild thrombocytopenia, and slightly altered plasma concentrations of 
coagulation factors and physiological anticoagulants argue for a specific form of 
intravascular coagulation in severe COVID-19 that is distinguishable from classical 
DIC seen in sepsis53. The prominent increase in vascular complications points to 
strong involvement of endothelial cells in hemostatic abnormalities seen in COVID-
19. Injured endothelial cells may provide a scaffold for thrombus generation and 
elevated levels of von Willebrand factor multimers (recently described in COVID-19 
plasma54) may facilitate platelet-vessel wall interactions ultimately leading to the 
formation of platelet-rich thrombotic deposits in microvasculature. Such platelet-rich 
thrombotic aggregates have been observed in alveolar capillaries of critically ill 
COVID-19 patients16,17. Altogether haemostatic alterations seen in COVID-19 
subjects reflect widespread occlusive thrombotic microangiopathy with destruction of 
alveoli that supports persistence of microthrombi. 
Increased levels of fibrinogen and elevated thrombin generation potential were found 
to contribute to the formation of stable clots that are composed of a dense network of 
the thin fibrin strands36,55. Accordingly, clots generated in COVID-19 plasma exhibited 
higher packing density and were more resistant to lysis as compared to clots formed 
in ARDS-influenza plasma. Further experiments with COVID-19 plasma revealed that 
next to fibrinogen also FXIIa may regulate clot compactness. While, increased 
fibrinogen levels can independently promote thrombus formation and stability55, the 
role of FXII in this process seems to be more complex and dependent on the 
presence of cofactors, which enable FXII (auto)-activation. FXIIa may then regulate 
fibrin network density in a thrombin-dependent and a thrombin-independent manner. 
While, the ability of FXIIa to convert factor XI (FXI) to FXIa and thereby to promote 
thrombin generation is well documented56,57, elucidation of the mechanism of a direct 
effect of FXIIa on fibrin clot architecture requires further research. FXIIa binds with 
high affinity to fibrinogen/fibrin36, whether this interaction facilitates fibrin fiber cross-
linking or incorporation of other components into a clot is speculative at the 
movement. Though, high turbidity of fibrin clots observed in COVID-19 may speak for 
the intercalation of, e.g. NET components, into the fibrin network. Cell free-DNA and 
histones (both NET components) were found to promote more opaque and 
fibrinolysis resistant clots58,59. In addition, cell free-DNA was reported to bind to 

































































































































intercalation into fibrin network could not only accelerate FXII auto-activation but also 
serve as a platform that brings plasma-proteins and fibrin fibers together resulting in 
the formation of turbid and fibrinolysis resistant clots.  
The persistent vessel occlusion, seen in critically ill COVID-19 patients, seems to be 
reinforced by markedly increased plasma levels of TAFI and moderately increased 
amounts of PAI-1. Elevated levels of t-PA try to counterbalance this prothrombotic 
environment, however, are not sufficient to compensate for increased procoagulant 
activity in patients with COVID-19. These findings are supported by recently 
published results showing that the enhanced thrombin generation potential is not 
adequately offset by increased plasmin generation potential in COVID-1952.  High 
levels of fibrinogen and accelerated rate of FXIIa formation seem to potentiate this 
effect.  
Our study has several limitations. First, the number of patients with COVID‐19 and 
patients with ARDS-influenza is small and samples were collected at a single time 
point. Second, most of the patients with COVID‐19 and patients with ARDS-influenza 
were receiving anticoagulant therapy. Five of the ARDS-influenza patients and seven 
of the patients with COVID-19 did not receive anticoagulation. However, we did not 
observe any differences in the parameters measured in the patients with or without 
anticoagulation. Third, although demographics and baseline laboratory values of 
ARDS-influenza and COVID-19 patients are comparable, there are some significant 
differences, e.g. in CRP or procalcitonin values, which might have an impact on our 
results. Yet, exclusion of the ARDS-influenza cases with the highest CRP or 
procalcitonin values did not change our results. Fourth, blood samples used in this 
study were not supplemented with contact phase pathway inhibitors, therefore, 
changes in the activation status of the contact phase proteins during blood sampling 
cannot be excluded. However, all samples were collected in the same manner. 
Finally, the measurements of plasma function in ARDS-influenza and COVID-19 
were performed in vitro, hence, they may not fully reflect the processes occurring in 
vivo. Thus, further mechanistic studies ex vivo and in vivo are needed to fully 
elucidate the procoagulant and fibrinolytic changes in ARDS-influenza and COVID-
19.  
In conclusion, pathological events described in COVID-19 create milieu favoring 

































































































































to compact, lysis resistant clot formation in a thrombin-dependent and a thrombin-
independent manner. This prothrombogenic microenvirement is further promoted by 
dysregulated fibrinolysis. Our study advances understanding of the common and 
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of the adhesive blood-protein von Willebrand factor guided by electrostatic 


































































































































Table 1. Baseline demographics and clinical characteristics of donors and COVID-19 and ARDS-influenza 
patients (plasma samples).  










No. of patients, n 25 21 21 15 15 15 
Age, year 56;[20-86] 59;[19-82] 60;[20-79] 61;[22-84] 61;[26-80] 61;[24-82] 
Sex, male (%) 87  90 88 69 67 68 
BMI (kg/m2) 25;[20-36] 29 [15-62] 26;[19-45] 29;[25-36] 24;[20-36] 25;[22-37] 
3CRB65 score, n       
       0 0 0  NA NA  
       1 3 2     
       2 5 6     
       3 12 9     
       4 5 4     
28-day mortality (%) 30 14.3  8 0  
4LOS ICU, days 19;[6-73] 27;[3-63]  30;[5-220] NA  
Ventilation, days 15;[3-66] 16;[4-50]  26;[5-220] NA  
5ECMO (%) 30 24  46 NA  
6SOFA 10;[5-16] 13;[9-17]  10;[2-12] NA  
4CRP (mg/L) 264;[31-406] 151;[68-292]  85;[27-411] 29;[1-148]  
Leukocytes, 109/L 16;[22-90] 9;[4-36]  10;[5-27] 7;[4-22]  
Platelets, 109/L 199;[70-653] 247;[99-581]  286;[129-635] 334;[173-602]  
Lactate, mM 1.3;[0.7-4.8] 1.8;[0.7-5.6]  1.7;[0.4-6.6] 1.3;[1.0-2.6]  
Procalcitonin, µg/L 1.7;[0.2-79.5] 0.6;[0.1-66.1]  0.6;[0.1-25] 0.1;[0-1]  
D-dimer, mg/L NA 4; [1-35]  NA NA  
Fibrinogen, g/L 4.0 [3.2-9.0] 8.0; [4.0-9.0]  NA NA  
Anticoagulant       
      Heparin, n 15  14  8 7  
8PTT, s 38;[25-59] 36;[26-55]  41;[30-67] 34;[30-60]  
1ARDS, acute respiratory distress syndrome; 2COVID-19, coronavirus disease 2019;  3CRB 65, confusion, 
respiratory rate, blood pressure, age 65 score; 5LOS ICU, length of intensive care unit stay, ; 5ECMO, 
extracorporeal membrane oxygenation; 6SOFA, sequential organ failure assessment;  7CRP, C-reactive 


































































































































Table 2. Baseline demographics and clinical characteristics of donors, COVID-19 and ARDS-influenza patients 
(lung tissue).  
 
1COVID-19   
Patient Age, 
year 
Sex Background Ventilation, 
days 
Anticoagulant 
1 82 Male Diffuse alveolar damage 0 Heparin 
2 77 Male Diffuse alveolar damage 2 Heparin 
3 72 Male Diffuse alveolar damage 6 Heparin 
4 65 Male Diffuse alveolar damage 33 Heparin 
5 79 Female Diffuse alveolar damage 2 Heparin 
2ARDS-influenza   
1 67 Male 3CAP 6 Heparin 
2 72 Male CAP 10 Heparin 
3 77 Male CAP 5 Heparin 
4 81 Female CAP 10 Heparin 
5 80 Female CAP 3 Heparin 
Donor   
1 82 Female Recurrent myocardial infarction 0 no 
2 75 Female Heart and lung failure 0 Heparin 
3 64 Male Myocardial infarction 0 Heparin 
4 77 Female Dilated cardiomyopathy (right) 0 Heparin  
5 75 Male Dilated cardiomyopathy (right) 0 Heparin 



































































































































Figure 1. Activation of the contact phase system in plasma of critically ill 
COVID-19 patients. A,C) Western blot analysis (left panels) of factor XII (FXII) A) 
and high molecular weight kininogen (HK) C) in plasma from moderate and severe 
COVID-19 patients (infected with SARS-CoV2) and donors (healthy subjects). Four 
out of 15 moderate and severe COVID-19 patients and 3 out of 15 donors are 
demonstrated. Albumin was used as a loading control. Rights panels show the 
specificity of the antibodies used. B, D) Densitometric analysis of A) and C), 
respectively. COVID-19 moderate/severe n=15, donor n=15. E) PKa-like activity in 
plasma from moderate (n=14) and severe (n=14) COVID-19 patients and donors 
(n=15). F) Correlation between the levels of intact HK and PKa-like activity in plasma 
of severe Covid-19 patients. n=14. Correlation is performed using Spearman’s rank 
correlation coefficient. *p<0.05, **p<0.01, ***p<0.001.  
Figure 2. Formation of dense fibrin clots in plasma of severe COVID-19. A) 
Western blot analysis of factor XII (FXII) in plasma from ARDS-influenza (Influenza) 
and COVID-19 (SARS-CoV2) patients as well as donors. Four out of 21 COVID-19 
patients, 4 out of 25 ARDS-influenza patients, and 3 out of 21 donors are 
demonstrated. Albumin was used as a loading control. B) FXII levels in plasma of 
ARDS-influenza (n=25) and COVID-19 (n=21) patients as well as donors (n=16) as 
assessed by ELISA. C) Lag phase in fibrin formation-triggered by kaolin. Influenza, 
n=19; SARS-CoV2, n=20; donor, n=20. D) FVIII activity (FVIII:C) in plasma of 
patients and donors. Influenza, n=19; SARS-CoV2, n=20; donor, n=20. E, F) Time to 
reach the turbidity peak E) and maximum (Max) turbidity F) values for Influenza 
(n=19), SARS-CoV2 (n=20) and donor (n=20) plasma. Clot formation was induced by 
the addition of kaolin to plasma. G) Laser scanning confocal microscopy images of 
fibrin fibers in clots formed from Influenza (n=19), SARS-CoV2 (n=20), and donor 
(n=20) plasma. Representative pictures are demonstrated. H) Scanning electron 
microscopy images of fibrin network in clots generated from Influenza (n=5) as well 
as low- and high-fibrinogen SARS-CoV2 (n=5/group) plasma. Representative 
pictures are demonstrated. I) Fibrin fiber density in donor (n=20), ARDS-Influenza 
(n=19) and COVID-19 (n=20) clots. Per patient 3 separate clots were prepared, 5 
pictures were taken in different areas of the clots and fibril density was determined in 
all pictures. J)  Correlation between Max turbidity values and fibrinogen levels in 

































































































































levels were included into the analysis). Correlation is performed using Spearman’s 
rank correlation coefficient. 
Figure 3. Impact of FXIIa on fibrin clot structure in severe COVID-19 plasma. A, 
B) Max turbidity values of fibrin clots generated in the purified system from increasing 
concentrations of fibrinogen and/or Factor XII (FXII)/active FXII (FXIIa) in the 
absence or presence of corn trypsin inhibitor (CTI). Clot formation was induced by 
thrombin. n=4-5. C) Laser scanning confocal microscopy images of fibrin fibers in 
clots formed from FXII-depleted SARS-CoV2 or Influenza plasma supplemented with 
FXII. Representative pictures are shown. D) Fibrin fiber density in ARDS-Influenza 
(n=10) and COVID-19 (n=10) clots generated in C). Per patient 3 separate clots were 
prepared, 5 pictures were taken in different areas of the clots and fibril density was 
determined in all pictures. Paired data is shown interconnected. E) Rate of FXII 
(auto)-activation in ARDS-Influenza and SARS-CoV2 plasma. FXII was added to 
FXII-depleted plasma and its decay was monitored by western blotting using an 
antibody directed against FXII. Representative blot is shown. F) Quantification of FXII 
decay in ARDS-Influenza and SARS-CoV2 plasma in E. FXII signal at time point 0 
was considered as 100%. n=20/group. G) Max turbidity values of fibrin clots 
generated by the addition of batroxobin to hirudin-preincubated plasma in the 
presence of FXIIa and/or CTI. n=15 biological replicates. *p<0.05, **p<0.01, 
***p<0.001. 
Figure 4. Dysregulated fibrinolysis in severe COVID-19. A) Turbidimetric analysis 
of clot lysis in severe COVID-19, ARDS-influenza and donor plasma. Representative 
clot lysis curves are shown. SARS-CoV2, n=20; ARDS-Influenza; n=19, donors, 
n=20. B) Turbidity values of the fibrin clots at 60 min. SARS-CoV2, n=20; ARDS-
influenza, n=19; donors, n=20. C, D) Clot lysis time. Clots were generated in purified 
system with increasing concentrations of fibrinogen and/or factor XII (FXII)/active FXII 
(FXIIa). Clot formation was induced by thrombin and clot lysis by plasmin generated 
from plasminogen by tissue-plasminogen activator (t-PA). In some experiments FXII 
was preincubated with corn trypsin inhibitor (CTI). Clot formation and lysis were 
monitored via turbidimetry. n=3-5. *p<0.05, **p<0.01. E-G) t-PA (E), plasminogen 
activator inhibitor-1 (PAI-1; F), and thrombin-activatable fibrinolysis inhibitor (TAFI, G) 
levels in plasma of COVID-19 (n=21), ARDS-influenza (n=21) and donors (n=17) as 

































































































































Figure 5. High abundance of fibrin deposits in the lungs of severe COVID-19 
patients. A, B) Fibrin (red) accumulation in postmortem lung tissue sections of 
severe COVID-19, ARDS-influenza, and donors (n=5/group). Time from death to 
autopsy was matched for all groups examined. Magnification bar 100 µm. B shows 
randomly chosen high magnification images of COVID-19 and ARDS-influenza clots 
presented in A.  Arrows indicate fibrin deposits. All patients available are 
demonstrated. C) Fibrin abundance in COVID-19, ARDS-Influenza, and donor lungs. 
Per patient 5 pictures were taken in different areas of the lung and % of total area 
was determined in all pictures. n=5/group. *p<0.05, **p<0.01. D) Fibrin fiber density 
in COVID-19 and ARDS-Influenza lungs. Per patient 5 images of fibrin deposits were 
taken and fibril density was determined in all pictures. n=5/group. 
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